Literature DB >> 27783170

Assessment of ataxia phenotype in a new mouse model of galactose-1 phosphate uridylyltransferase (GALT) deficiency.

Wyman Chen1, Rose Caston1,2, Bijina Balakrishnan1, Anwer Siddiqi3, Kamalpreet Parmar3, Manshu Tang1, Merry Feng1, Kent Lai4.   

Abstract

Despite adequate dietary management, patients with classic galactosemia continue to have increased risks of cognitive deficits, speech dyspraxia, primary ovarian insufficiency, and abnormal motor development. A recent evaluation of a new galactose-1 phosphate uridylyltransferase (GALT)-deficient mouse model revealed reduced fertility and growth restriction. These phenotypes resemble those seen in human patients. In this study, we further assess the fidelity of this new mouse model by examining the animals for the manifestation of a common neurological sequela in human patients: cerebellar ataxia. The balance, grip strength, and motor coordination of GALT-deficient and wild-type mice were tested using a modified rotarod. The results were compared to composite phenotype scoring tests, typically used to evaluate neurological and motor impairment. The data demonstrated abnormalities with varying severity in the GALT-deficient mice. Mice of different ages were used to reveal the progressive nature of motor impairment. The varying severity and age-dependent impairments seen in the animal model agree with reports on human patients. Finally, measurements of the cerebellar granular and molecular layers suggested that mutant mice experience cerebellar hypoplasia, which could have resulted from the down-regulation of the PI3K/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27783170      PMCID: PMC5203948          DOI: 10.1007/s10545-016-9993-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  The neuropathology of galactosemia. A histopathological and biochemical study.

Authors:  C Haberland; M Perou; E G Brunngraber; H Hof
Journal:  J Neuropathol Exp Neurol       Date:  1971-07       Impact factor: 3.685

2.  Leptin attenuates cerebral ischemia injury through the promotion of energy metabolism via the PI3K/Akt pathway.

Authors:  Jinying Zhang; Zihui Deng; Jie Liao; Cuihong Song; Chen Liang; Hui Xue; Luhuan Wang; Kai Zhang; Guangtao Yan
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-09       Impact factor: 6.200

3.  Motor and speech disorders in classic galactosemia.

Authors:  Nancy L Potter; Yves Nievergelt; Lawrence D Shriberg
Journal:  JIMD Rep       Date:  2013-04-02

4.  PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro.

Authors:  Li Zhang; Yi Qu; Jun Tang; Dapeng Chen; Xuemei Fu; Meng Mao; Dezhi Mu
Journal:  Brain Res       Date:  2010-08-10       Impact factor: 3.252

5.  The adult galactosemic phenotype.

Authors:  Susan E Waisbren; Nancy L Potter; Catherine M Gordon; Robert C Green; Patricia Greenstein; Cynthia S Gubbels; Estela Rubio-Gozalbo; Donald Schomer; Corrine Welt; Vera Anastasoaie; Kali D'Anna; Jennifer Gentile; Chao-Yu Guo; Leah Hecht; Roberta Jackson; Bernadette M Jansma; Yijun Li; Va Lip; David T Miller; Michael Murray; Leslie Power; Nicolle Quinn; Frances Rohr; Yiping Shen; Amy Skinder-Meredith; Inge Timmers; Rachel Tunick; Ann Wessel; Bai-Lin Wu; Harvey Levy; Louis Elsas; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2011-07-21       Impact factor: 4.982

6.  A Drosophila melanogaster model of classic galactosemia.

Authors:  Rebekah F Kushner; Emily L Ryan; Jennifer M I Sefton; Rebecca D Sanders; Patricia Jumbo Lucioni; Kenneth H Moberg; Judith L Fridovich-Keil
Journal:  Dis Model Mech       Date:  2010-06-02       Impact factor: 5.758

7.  Subfertility and growth restriction in a new galactose-1 phosphate uridylyltransferase (GALT) - deficient mouse model.

Authors:  Manshu Tang; Anwer Siddiqi; Benjamin Witt; Tatiana Yuzyuk; Britt Johnson; Nisa Fraser; Wyman Chen; Rafael Rascon; Xue Yin; Harish Goli; Olaf A Bodamer; Kent Lai
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

8.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09

9.  Galactose-1 phosphate uridylyltransferase (GalT) gene: A novel positive regulator of the PI3K/Akt signaling pathway in mouse fibroblasts.

Authors:  Bijina Balakrishnan; Wyman Chen; Manshu Tang; Xiaoping Huang; Didem Demirbas Cakici; Anwer Siddiqi; Gerard Berry; Kent Lai
Journal:  Biochem Biophys Res Commun       Date:  2016-01-08       Impact factor: 3.575

10.  A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia.

Authors:  Stephan J Guyenet; Stephanie A Furrer; Vincent M Damian; Travis D Baughan; Albert R La Spada; Gwenn A Garden
Journal:  J Vis Exp       Date:  2010-05-21       Impact factor: 1.355

View more
  6 in total

1.  Salubrinal enhances eIF2α phosphorylation and improves fertility in a mouse model of Classic Galactosemia.

Authors:  B Balakrishnan; A Siddiqi; J Mella; A Lupo; E Li; J Hollien; J Johnson; K Lai
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-07-27       Impact factor: 5.187

2.  Impaired fertility and motor function in a zebrafish model for classic galactosemia.

Authors:  Jo M Vanoevelen; Britt van Erven; Jörgen Bierau; Xiaoping Huang; Gerard T Berry; Rein Vos; Ana I Coelho; M Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2017-09-14       Impact factor: 4.982

3.  A galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism.

Authors:  Shauna A Rasmussen; Jennifer M I Daenzer; Jessica A MacWilliams; S Taylor Head; Martine B Williams; Aron M Geurts; Jason P Schroeder; David Weinshenker; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2019-12-29       Impact factor: 4.982

Review 4.  Pathophysiology and targets for treatment in hereditary galactosemia: A systematic review of animal and cellular models.

Authors:  Minela Haskovic; Ana I Coelho; Jörgen Bierau; Jo M Vanoevelen; Laura K M Steinbusch; Luc J I Zimmermann; Eduardo Villamor-Martinez; Gerard T Berry; M Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2020-01-14       Impact factor: 4.982

5.  Harnessing the Power of Purple Sweet Potato Color and Myo-Inositol to Treat Classic Galactosemia.

Authors:  Synneva Hagen-Lillevik; Joshua Johnson; Anwer Siddiqi; Jes Persinger; Gillian Hale; Kent Lai
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

Review 6.  Pathophysiology and management of classic galactosemic primary ovarian insufficiency.

Authors:  Synneva Hagen-Lillevik; John S Rushing; Leslie Appiah; Nicola Longo; Ashley Andrews; Kent Lai; Joshua Johnson
Journal:  Reprod Fertil       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.